Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

• Patients must have probable Alzheimer's disease of mild or moderate severity.

• A brain scan and laboratory results must be consistent with Alzheimer's disease.

• The patient must be otherwise medically healthy.